The Scrip Awards is independently judged. Judging will take place in July 2008. The Judging Panel comprises independent, senior industry experts from around the world, chosen for their knowledge, objectivity and credibility. Judges mark entries in categories relevant to their specialist knowledge, expertise and experience, ensuring a considered, educated response to your submission.
Once entries have been received and processed they will be distributed to the relevant judges. The judges will use the published criteria against which to score each entry. The judges then submit their scores, which are collated to decide the winner of each Award. A shortlist of the entries will be published; however details of the winners will be embargoed and revealed only on the night of the Awards ceremony itself.
The chair of the Judging Panel reserves the right to cast any deciding vote, should the need arise. The judges’ decision is final and neither the organisers nor the Judging Panel will enter into any correspondence about the results.
Richard Barker is director general of the Association of the British Pharmaceutical Industry, a board member of EFPIA (the European industry association) and council member of IFPMA (the International equivalent). He is a member of the NHS Stakeholder Forum, the UKCRC and the OSCHR E-Health Research Board. In the biotechnology sector, he is a board member of Adlyfe, developing detection technology for diseases involving protein misfolding, and of iCoTherapeutics, an early stage company developing ocular therapies.
Anthony Butler was Japan’s representative at PhRMA (Pharmaceutical Research and Manufacturers of America) until the end of April 2006. Before joining PhRMA in 2001, Mr Butler was vice-president for business development at Pharmacia (and Pharmacia & Upjohn), having served previously as vice-president for Japan, Europe and Latin America at the company. Mr Butler began his pharmaceutical career in 1966 at the Upjohn Company, joining its international division in 1975, for which he worked in Africa, Europe, Latin America, the US and Japan.
Professor Trevor Jones CBE is a director of Allergan, Sigma-Tau, NextPharmaTechnolgies, VeronaPharma, ReNeuron and Synexus. Between 1987 and 1994, he was a main board director of The Wellcome Foundation, where he was responsible for R&D. He is a founder member of the Medicines for Malaria Venture and in 2004 was appointed to the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health. He was previously a member of the UK Medicines Commission and Director General of the Association of the British Pharmaceutical Industry. He won Scrip’s Lifetime Achievement Award in 2005.
Dr Bernard Lemoine represents the French federation of healthcare industries (Féfis) on the executive committee of the French employers' federation (Medef). Until the end of January 2009, he was executive vice-president of Leem, the French pharmaceutical industry association, and, between 1979 and 1988, was the internal affairs director then deputy director general of Fournier Laboratories. Dr Lemoine is a member of the board of directors and on the board of both EFPIA (European Federation of Pharmaceutical Industries and Associations) and the IFPMA (International Federation of Pharmaceutical Manufacturers Associations).
Professor Rolf Krebs joined Bayer AG in Wuppertal in 1976 and became head of Bayer’s Worldwide Pharmaceutical R&D Department and head of the Pharma Sector R&D Coordination Committee in 1984. In 1989 he became a managing partner at C H Boehringer Sohn and vice-chairman of the board of managing directors at Boehringer Ingelheim. In 2001 he became chairman of the board of directors. From 1998 to 2000 he was president of EFPIA and from 2000 to 2002 he was president of IFPMA. He is currently chairman of the supervisory board of Epigenomics AG. He won Scrip’s Lifetime Achievement Award in 2006.
Dr Mehta is the founder of Mehta Partners LLC, an independent advisory firm to life science pharma and biotechnology companies worldwide. For over 20 years his work has focused on global strategic consulting as well as research for the investment industry. Prior to pioneering the in-depth sciencedriven valuation of the BioPharma industry, Dr Mehta was a part of the strategic planning team of the International division at Merck & Co and earned a Doctor of Pharmacy at the University of Southern California, and an MBA from the University of California, Los Angeles.
Professor Rainer Müller has been professor of pharmaceutics and biopharmaceutics at the Free University in Berlin since 1991. There his research focuses on poorly soluble drugs. He is inventor on various patent families of drug nanocrystals (eg DissoCubes®, smartCrystals®) and of lipid nanoparticles (SLN®, NLC®). In 1999 he founded the company PharmaSol in Berlin which is a nanotechnology company for formulation development and IP licensing. Since 2006 PharmaSol introduced about 30 NLC and smartCrystal licensed products to the cosmetic market and licensed the technologies also to pharmaceutical industry (eg Soliqs).
Phornvit Phacharintanakul is chairman of Strategic Business Partners in Bangkok, Thailand. Until the end of 2004 he was chairman of the board at Aventis Thailand, where he previously held a range of posts including managing director and marketing manager. Before joining Aventis, he was on the secretariat of the United Nations Economic Commission for Asia and the Pacific. Mr Phacharintanakul also acts as an expert advisor for the Thailand Center of Excellence for Life Sciences.
Peter Pitts is director of the Center for Medicine in the Public Interest, a think-tank on public healthcare policy issues, and senior vice-president and director for global health affairs for Manning, Selvage & Lee. Between 2002 and 2004, Mr Pitts was the US FDA’s associate commissioner for external relations, acting as the senior communications advisor to Dr Mark McClellan. He also served on the agency’s obesity working group and counterfeit drug taskforce. Before his work with the FDA, Mr Pitts was the managing partner of Wired World, a strategic public awareness company.
Dr Robert Ruffolo is a consultant for Wyeth Pharmaceuticals, having retired in 2008 as president of research and development at the company and as senior vice-president of Wyeth Corporation. Before joining Wyeth, Dr Ruffolo spent 17 years with SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), where he played a significant role in the discovery and development of a number of products, including the heart failure drug, carvedilol (Coreg/Dilatrend), and the Parkinson's disease therapy ropinirole (Requip). Dr Ruffolo was awarded Scrip's Lifetime Achievement Award in 2008.
Dr Brian Tempest is chairman of Hale & Tempest Co. He has 38 years' experience in the pharmaceutical industry, and between 1995 and 2007 held senior executive positions, including president and CEO, at Ranbaxy Laboratories, where he is now a nonexecutive director. Previously Dr Tempest was Far East regional director for Glaxo, and has led healthcare businesses, R&D organisations and global manufacturing concerns. Dr Tempest also acts as an advisor to financial institutions and as a lecturer on the emerging markets of China and India.
Julian Thurston is a partner in Morrison & Foerster's Technology Transactions Group and co-chair of the Life Sciences Group. He is a leading UK life sciences transactional attorney with expertise in commercial exploitation, protection and strategic planning issues, particularly within the biotech and medical device sectors. Mr Thurston is one of the first UK attorneys to focus on life sciences transactions, and has developed a strong position in the market, and has particular expertise in representing biotechs in IP licensing, strategic partnering and other collaboration matters.
